PIRS News and Press, Pieris Pharmaceuticals Inc. From 09/26/19

Marinus Pharmaceuticals (NASDAQ: MRNS ) +39%  on positive ganaloxone data . More news on: Marinus Pharmaceuticals, Inc., Pieris Pharmaceuticals, Inc., SAExploration Holdings, Inc., Stocks on the move, Read more ...

Noteworthy events during the week of September 22 - 28 for healthcare investors. More news on: UroGen Pharma Ltd., Medtronic plc, ENDRA Life Sciences Inc., Healthcare stocks news, , Read more ...

There is no worse tyranny than to force a man to pay for what he does not want merely because you think it would be good for him ." - Robert A. Heinlein, The Moon is a Harsh Mistress Today, we revisit Pieris Pharmaceuticals ( PIRS ) as we have not looked in on this intriguing ' Tier 4 '...

The following slide deck was published by Pieris Pharmaceuticals, Inc. in conjunction with this Read more ...

Pieris Pharmaceuticals (NASDAQ: PIRS )  appoints Hitto Kaufmann, Ph.D. as Senior Vice President and Chief Scientific Officer. More news on: Pieris Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

BOSTON, MA / ACCESSWIRE / September 3 , 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today annou...

BOSTON, MA / ACCESSWIRE / August 29, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer and other indicatio...

Pieris Pharmaceuticals, Inc. (PIRS) Q2 2019 Results Conference Call August 1, 2019 8:00 AM ET Company Participants Allan Reine – Chief Financial Officer Steve Yoder – President and Chief Executive Officer Lou Matis – Senior Vice President and Chief Developmen...

Company to Host an Investor Conference Call on Thursday, August 1, 2019 at 8:00 AM EDT BOSTON, MA / ACCESSWIRE / August 1, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through ...

BOSTON, MA / ACCESSWIRE / August 1, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS ) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, to...